N Engl J Med 2017 Jun 1
Myeloproliferative Neoplasms.
Related Questions
In someone with an asymptomatic JAK2 V617 mutated and BCR/ABL negative MPN with a steadily rising WBC, when do you decide to start cytoreductive therapy and which agent(s) do you recommend?
First, let's abandon the phase "BCR/ABL-negative MPN". This is an oxymoron because BCR/ABL can be expressed in a JAK2 driver mutation-positive MPN. In fact, both BCR/ABL and JAK2 mutations can be expressed in normal individuals at very low levels without causing disease. Both mutations can also be p...
How do you manage recurrent portal vein thromboses in a patient with JAK2+ PV on therapeutic anticoagulation and appropriate cytoreduction?
How do you manage recurrent portal vein thromboses in a patient with JAK2+ PV on therapeutic anticoagulation and appropriate cytoreduction? Recurrent thromboses despite therapeutic enoxaparin. Other hypercoagulable work-up negative. This clinical situation is one of the three pressing unresolved pro...
How do you differentiate between JAK2 positive ET and PV when peripheral blood shows erythrocytosis and thrombocytosis?
The answer to this question is very simple. Before the discovery of erythropoietin and accurate assays for it, and before the discovery of JAK2 driver mutations, the diagnosis of polycythemia vera was clinically-based. The Polycythemia Vera Study Group (PVSG) did an extensive epidemiologic study and...